Ophthalmology September 2023 PMID 37318415

Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results.

Download social card

Mentions

Peak: 2 in Oct 2023

across 5 sources since Jun 2023

Extended reach

26,900

potential audience

Total likes

Video views

Mentions per month

Jun 2023 – Jun 2025

Where it's discussed

News34 articles
X / Twitter3 posts
Blogs3 articles
YouTube2 videos
Bluesky1 posts

AI synopsis

What people are saying

Several discussions emphasize the importance of the MERIT trial, using phrases like 'significant improvement' and 'most effective treatment,' reflecting high interest and recognition of impact. References to infographics and summarizations suggest active engagement, though the tone remains mainly informational rather than deeply analytical.

AgreementModerate agreement

Most discussions support the findings, highlighting the effectiveness of dexamethasone and the significance of the trial results.

InterestHigh interest

The posts show high interest, with many referencing the clinical implications and summarizing the key outcomes of the study.

EngagementModerate engagement

Participants actively engage by sharing infographics and discussing the comparative results, indicating moderate depth of discussion.

ImpactModerate impact

The messages convey that the trial's results could influence treatment decisions, emphasizing its clinical importance.

Abstract in brief

The MERIT trial compared three intravitreal treatments—dexamethasone implant, methotrexate, and ranibizumab—for uveitic macular edema, focusing on their ability to reduce retinal swelling and improve visual acuity.
Results at 12 weeks showed all treatments significantly reduced macular thickness, with dexamethasone being the most effective, and only dexamethasone leading to a notable improvement in vision.
Although dexamethasone caused more frequent increases in eye pressure (a potential side effect), serious pressure spikes were rare, and all treatments demonstrated some level of benefit in managing uveitic macular edema.]

Read the full abstract

All mentions

Comparison of Intravitreal Treatments for Uveitic Macular Edema

Dr. Jabs and Dr. Acharya review the MERIT trial comparing dexamethasone, ranibizumab, and methotrexate for uveitic macular edema. The study highlights efficacy in reducing retinal swelling and visual outcomes, with…

The Retina Channel Podcast · Oct 28, 2023 33 views

Comparison of Intravitreal Dexamethasone, Ranibizumab, and Methotrexate for Uveitic Macular Edema

Dr Jabs and Dr Acharya discuss the MERIT trial comparing intravitreal treatments for uveitic macular edema. The study evaluated efficacy in reducing retinal swelling and improving vision, with dexamethasone showing the…

The Retina Channel Podcast · Oct 28, 2023 18 views

Ophthopedia

@ophthalmology.bsky.social · Bluesky

Jun 2, 2025 View post →

rajesh garg

@gargrajeshindia · X

RT @AAOjournal: 8. Intravitreal Therapy for Uveitic Macular Edema—Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MER…

Dec 28, 2023 · 1 share · 125 followers View post →

Ophthalmology

@AAOjournal · X

Dec 27, 2023 · 2 likes · 1 share · 24,223 followers View post →

Ophthopedia

@ophthopedia · X

Ophthopedia Update: Intravitreal Therapy for Uveitic Macular Edema—Ranibizumab versus Methotrexate versus the Dexamethasone Implant #Ophthalmology #ophthotwitter #eyecare https://t.co/KlG0kcnSYP

Jun 13, 2023 · 2,497 followers View post →